.jpeg)
2026-09-04 06:41:27
Ruxolitinib Cream (Opzelura) is a topical JAK inhibitor for mild-to-moderate atopic dermatitis and vitiligo. This article details application methods, differences between indications, local precautions, side effects, and efficacy expectations.
2026-09-03 06:11:28
Bedaquiline (Sirturo) is used for drug-resistant tuberculosis. This article explains its drug interactions, focusing on CYP3A4 inducers/inhibitors and QT-prolonging agents, to ensure treatment safety.
2026-09-03 05:11:16
Learn about Acalabrutinib (Calquence) recommended dosage (100mg twice daily), continuous treatment approach for CLL, MCL and SLL, administration tips, and adverse reaction management.
2026-09-02 07:24:03
Epclusa (Sofosbuvir/Velpatasvir) is the first pan-genotypic direct-acting antiviral regimen for chronic hepatitis C. This article details its dual-target mechanism, comparison with other DAAs, Child-Pugh guided regimens, and special population strategies.
2026-09-02 07:16:43
Lao Biktarvy is a generic version of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) produced in Laos for HIV-1 infection. This article explains its bioequivalence, comparison with other regimens, treatment-naïve and switch strategies, drug interactions, and monitoring.
2026-09-02 05:52:04
Finerenone is a non-steroidal selective mineralocorticoid receptor antagonist for chronic kidney disease associated with type 2 diabetes and for heart failure with LVEF ≥40%, adding a third pathway alongside RAAS and SGLT2 inhibitors.
2026-09-01 04:42:07
Selpercatinib is an oral RET inhibitor for RET fusion–positive NSCLC, thyroid cancer and other solid tumors, and RET-mutant medullary thyroid cancer. Dosing is weight-based, and acid-reducing agents require attention.
2026-09-01 04:25:06
Enasidenib is an oral small-molecule inhibitor of mutant IDH2. By lowering the oncometabolite 2-hydroxyglutarate (2-HG) and promoting myeloid differentiation, it is used in relapsed or refractory AML with an IDH2 mutation.
2026-09-01 03:28:25
Alpelisib is an oral PI3Kα inhibitor marketed as Piqray with fulvestrant for PIK3CA-mutated HR+/HER2− advanced breast cancer, and as Vijoice for PIK3CA-related overgrowth spectrum (PROS).
2026-09-01 03:18:35
Five-year OPTIC data show that response-based ponatinib dosing — starting at 45 mg and reducing to 15 mg after response — delivers durable molecular responses and long-term survival in third-line chronic-phase CML, with a markedly improved safety profile.
2026-09-01 03:12:01
Erdafitinib is an oral small-molecule FGFR tyrosine kinase inhibitor supplied as film-coated tablets, commonly available in 3 mg, 4 mg, and 5 mg strengths, with individualized dose adjustment.
2026-08-31 03:59:58
Capmatinib is a highly selective MET inhibitor for metastatic NSCLC harboring MET exon 14 skipping mutations, with efficacy established by the GEOMETRY mono-1 trial in both first-line and previously treated settings.
